SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics

Rhea-AI Summary

SciSparc (Nasdaq: SPRC) reported that its subsidiary NeuroThera Labs’ quantum sampling workflow platform for clinical trials data analytics has demonstrated a complete end-to-end hybrid quantum-classical workflow in a quantum simulation environment. The Platform processed real-world clinical data from secure ingestion and preparation through quantum-enabled analysis to biologically and clinically interpretable insights.

According to SciSparc, the proprietary framework is designed to enable quantum-enhanced sampling for continuous probability distributions in advanced statistical analyses of complex, high-dimensional biomedical and clinical trial datasets. Development plans include scaling supported datasets, further optimizing quantum algorithms, and running performance studies for clinical research, trial analytics and precision medicine. The Platform is advanced through CliniQuantum, in which NeuroThera holds 54.01%.

Market reaction after clinical data milestone: SPRC -5.76%

-5.76% $6.71

15m delay

-5.76% Vs previous close

$6.71 Last Price

$6.63 $8.25 Day Range

$3.85M Market Cap

0.2x Rel. Volume

Following this news, SPRC has declined 5.76%, reflecting a notable negative market reaction. Our momentum scanner has triggered 26 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $6.71.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The tag-specific record shows an average move of -2.17% across three events, framing this technology...

Analysis

The tag-specific record shows an average move of -2.17% across three events, framing this technology milestone against mixed precedent. The active F-3 resale registration and absence of quantified clinical outcomes remain relevant risks to monitor.

Key Figures

Announcement Date: July 31, 2026 NeuroThera Ownership: 54.01%

2 metrics

Announcement Date July 31, 2026 Article publication date

NeuroThera Ownership 54.01% Ownership interest in CliniQuantum

Previous Clinical trial Reports

3 past events · Latest: Jul 15 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 15	Phase IIb initiation	Positive	+14.8%	Phase IIb trial site initiated at Hannover Medical School for Tourette syndrome.
Dec 31	Trial approval renewal	Positive	-22.7%	Renewal approval received for Israeli medical cannabis agency autism trial.
Aug 19	Patient enrollment	Positive	+1.4%	First five patients enrolled and dosed in SCI-210 autism clinical trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific clinical-trial history was mixed: two aligned positive reactions and one divergence, averaging -2.17%.

Key Terms

hybrid quantum-classical workflow, quantum simulation environment, quantum-enhanced sampling, continuous probability distributions

4 terms

hybrid quantum-classical workflow technical

"complete end-to-end hybrid quantum-classical workflow capable of processing real-world clinical data"

A hybrid quantum-classical workflow is a computing process that splits a problem into parts handled by a quantum processor and parts handled by a conventional (classical) computer, with the two systems exchanging data and iterative results. Like a hybrid car that switches between electric and gasoline power to get the best performance, this setup lets each type of processor do what it does best. Investors care because the approach shapes how quickly and cost-effectively quantum advantages might reach real-world applications, affecting companies’ technology value, partnerships, and development timelines.

quantum simulation environment technical

"executed within a quantum simulation environment designed to emulate quantum computational processes"

A quantum simulation environment is software and hardware that imitates how quantum systems behave so researchers can model molecules, materials, or algorithms without needing a full-scale quantum computer. Think of it like a highly realistic flight simulator for quantum physics: it lets scientists test ideas, run experiments, and explore outcomes faster and cheaper than physical trials. For investors, these environments matter because they can accelerate research, lower development costs, and reveal commercial paths for quantum technology.

quantum-enhanced sampling technical

"designed to enable quantum-enhanced sampling for continuous probability distributions"

A computational technique that uses quantum computing principles to generate statistical samples more efficiently or accurately for complex problems, such as pricing models, risk simulations, or molecular simulations. Think of it as swapping a standard survey method for a new, higher-resolution tool that can find rare patterns or speed up calculations that classical computers struggle with. It matters to investors because improved sampling can change the reliability, cost, and timeline of research, forecasting, or product development that influence cash flow and competitive position.

continuous probability distributions technical

"quantum-enhanced sampling for continuous probability distributions relevant to advanced statistical analyses"

A family of mathematical models that describe the likelihood of different outcomes for variables that can take any value within a continuous range, using a probability density function where probability is defined over intervals rather than single points. They matter to investors because analysts and risk models use them to represent things like asset returns, interest rates, or forecast errors — like a smooth hill showing which outcomes are more or less likely and helping quantify risk and expected outcomes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, July 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced another technological milestone achieved by NeuroThera’s quantum sampling workflow platform for clinical trials data analytics (the “Platform”).

The Platform has successfully demonstrated a complete end-to-end hybrid quantum-classical workflow capable of processing real-world clinical data through a fully integrated analytical framework, from secure data ingestion and preparation, through quantum-enabled analytical processing, to the generation of biologically and clinically interpretable insights. The workflow was executed within a quantum simulation environment designed to emulate quantum computational processes relevant to the Platform's analytical architecture.

The Platform's proprietary analytical framework is designed to enable quantum-enhanced sampling for continuous probability distributions relevant to advanced statistical analyses of clinical trial and biomedical datasets.

This milestone confirms that the Platform can support a complete hybrid quantum-classical analytical workflow designed to address complex, high-dimensional biomedical datasets while applying quantum-inspired and quantum-enabled methodologies to uncover non-obvious patterns, all while maintaining alignment with downstream scientific interpretation requirements.

Building on this milestone, the Platform's development plan includes expanding the scale of supported datasets, further optimizing its quantum algorithms, and conducting performance studies designed to evaluate the potential contribution of quantum computing technologies to clinical research, clinical trial analytics and precision medicine applications.

The Platform is being advanced through CliniQuantum Ltd., a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics, in which NeuroThera holds 54.01%.

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the anticipated capabilities, performance, scalability and utility of NeuroThera's quantum platform and of the validated quantum sampling workflow; the continued development of the Platform through CliniQuantum Ltd. and expanding the scale of supported datasets, further optimizing its quantum algorithms and conducting performance studies designed to evaluate the potential contribution of quantum computing technologies to clinical research, clinical trial analytics and precision medicine applications. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

FAQ

What did SciSparc (NASDAQ: SPRC) announce about NeuroThera Labs' quantum Platform on July 31, 2026?

SciSparc announced that NeuroThera Labs’ Platform successfully demonstrated a complete end-to-end hybrid quantum-classical workflow for real-world clinical data. According to SciSparc, the workflow runs from secure data ingestion through quantum-enabled analysis to biologically and clinically interpretable insights within a quantum simulation environment.

What is NeuroThera Labs' hybrid quantum-classical workflow for clinical data analytics?

NeuroThera’s workflow is a fully integrated system that processes clinical data using both classical and quantum-enabled methods. According to SciSparc, it covers secure data ingestion, preparation, quantum-enhanced analytical processing, and generation of biologically and clinically interpretable insights within a quantum-relevant simulation environment.

How does NeuroThera's Platform use quantum computing in clinical trial analytics for SPRC investors?

The Platform applies quantum-enhanced sampling techniques to continuous probability distributions used in advanced statistical analyses. According to SciSparc, it targets complex, high-dimensional biomedical and clinical trial datasets, aiming to uncover non-obvious patterns while maintaining compatibility with downstream scientific and clinical interpretation requirements.

What future development plans exist for NeuroThera Labs' quantum Platform mentioned by SciSparc (SPRC)?

SciSparc reported that development plans include expanding the scale of supported datasets and further optimizing quantum algorithms. According to SciSparc, the team also intends to conduct performance studies on the Platform’s potential contribution to clinical research, clinical trial analytics and precision medicine applications.

What is CliniQuantum and how is it related to NeuroThera Labs and SciSparc?

CliniQuantum is a quantum-focused technology initiative developing proprietary computational solutions for complex clinical data analytics. According to SciSparc, NeuroThera Labs’ Platform is being advanced through CliniQuantum, and NeuroThera holds a 54.01% stake in this initiative, linking it to SciSparc through its subsidiary.

What type of clinical data can NeuroThera Labs' quantum Platform analyze?

The Platform is designed for advanced statistical analyses of clinical trial and broader biomedical datasets, especially complex, high-dimensional data. According to SciSparc, it supports continuous probability distributions and aims to reveal non-obvious patterns while remaining aligned with downstream biological and clinical interpretation needs.